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Introduction: Chronic skin ulcers, such as diabetic
ulcers, venous leg ulcers and pressure ulcers, are
intractable and increasing in prevalence, representing a
costly problem in healthcare. We developed a
combination therapy with a gelatin sheet, capable of
providing sustained release of platelet-rich plasma
(PRP). The objective of this study is to investigate the
safety and efficacy of autologous PRP covered with a
hydrocolloid dressing and PRP covered with a gelatin
sheet in the treatment of chronic skin ulcers.
Methods and analysis: Thirty patients with chronic
skin ulcers who have not healed with conventional
therapy for at least 1 month are being recruited. The
patients will receive PRP after debridement, and the
wounds will be covered with a hydrocolloid dressing or
gelatin sheet. The efficacy will be evaluated according
to the time from the beginning of PRP application to
secondary healing or the day on which wound closure
is achieved with a relatively simple surgical procedure,
such as skin grafting or suturing. All patients will be
followed up until 6 weeks after application to observe
adverse events related to the application of PRP and
the dressings. This study was designed to address and
compare the safety and efficacy of PRP covered with a
hydrocolloid dressing versus a gelatin sheet. If
successful, this combination therapy may be an
alternative to bioengineered skin substitutes containing
living cells and lead to substantial progress in the
management of chronic skin ulcers.
Ethics and dissemination: The study protocol was
approved by the Institutional Review Board of Kansai
Medical University (KMU Number 0649-1, 4 August
2014: V.1.0). The findings of this trial will be
disseminated through peer-reviewed journals, and
national and international scientific meetings as well as
to the patients.
Trial registration number: UMIN000015689.
INTRODUCTION
Chronic skin ulcers caused by diabetes melli-
tus, venous insufﬁciency, pressure sores,
collagen disease, trauma or radiation are
intractable and costly problems in health-
care.1–3 In particular, diabetic foot ulcers and
venous leg ulcers are frequent and costly
complications of the underlying diseases.
The prevalence of diabetic foot ulcers ranges
from 4% to 10% among patients with dia-
betes, and the lifetime incidence is reported
to be as high as 25%.2 3 It has been reported
that venous leg ulcers recur in 72% of cases,
and the recurrence rate after skin grafting is
48% within 1 year.4 With the development of
tissue engineering, bioengineered skin substi-
tutes and genetically derived growth factors
have progressed greatly in recent years with
respect to the treatment of chronic skin
ulcers.5–7 However, new treatment options
for chronic skin ulcers are needed.
Platelet-rich plasma (PRP) is blood plasma
enriched with platelets. Autologous PRP is a
source of autologous growth factors, such as
platelet-derived growth factor (PDGF), trans-
forming growth factor-β (TGF-β) and vascular
endothelial growth factor (VEGF).8 9 PRP has
been used clinically in a variety of treatments
for bone defects, tendon injuries, cartilage
injuries, cosmetic surgeries and chronic
ulcers.10 Regarding the efﬁcacy of PRP in the
treatment of chronic wounds, PRP has, in
Strengths and limitations of this study
▪ The current protocol will provide evidence to
compare the efficacy of platelet-rich plasma
(PRP) covered with a hydrocolloid dressing and
that of PRP covered with a gelatin sheet, in the
treatment of chronic skin ulcers.
▪ This study is a historical control study.
▪ Only subgroups are randomised, and the small
number of study participants may affect
generalisability.
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many reports, been described as improving the rate of
healing compared with standard care.11 12 On the other
hand, in other studies, no major differences have been
found in the healing outcomes of leg ulcers between PRP
treatment groups and control groups.11 12
A drug delivery system (DDS) is a type of technology
for enhancing the biological activity of growth factors
with a very short in vivo half-life after application.
Biodegradable hydrogels of gelatin with an isoelectric
point (IEP) of 5.0 have been designed and developed
for the sustained release of positively charged growth
factors, such as basic ﬁbroblast growth factor (bFGF),
PDGF-BB and TGF-β1.13–15 The efﬁcacy of a sustained
release system for epidermal growth factor was also
recently reported.16 PDGF-BB and TGF-β are major
growth factors involved in PRP for improving the wound
healing process, and enhanced angiogenesis by gelatin
microspheres impregnated with PRP has been
reported.13 Additionally, gelatin hydrogel sheets have
been used to achieve the sustained release of growth
factors and can be applied on wounds directly as a
wound dressing.17 The wound healing effect of PRP
covered with this sheet is expected to be enhanced by
the sustained release of growth factors from the gelatin
sheet as a result of its biodegradation after application.
In this report, we designed an exploratory clinical
study to investigate the safety and efﬁcacy of PRP appli-
cation covered with our gelatin sheet compared with
PRP covered with a hydrocolloid dressing, in the treat-
ment of chronic skin ulcers. In addition, we estimated
the contents of PDGF-BB, TGF-β1 and VEGF in PRP,
and compared these values and the degree of wound
healing associated with the gelatin sheet.
MATERIALS AND ANALYSIS
Primary objective
The objective of this study is to evaluate the safety and
efﬁcacy of the administration of PRP in the treatment of
chronic skin ulcers that are not expected to heal using
conventional treatments.
The safety and efﬁcacy of PRP covered with a gelatin
sheet versus a hydrocolloid dressing will also be
evaluated.
Methods and design
Open-label, non-randomised, controlled clinical trial.
Design
This study is a prospective cohort study using historical
data as a control. A group treated with PRP application
covered with a gelatin sheet and a group treated with
PRP application covered with a hydrocolloid dressing
have been set. Patients will be randomised to the gelatin
sheet subgroup or the hydrocolloid dressing subgroup,
and a randomisation-based comparison between these
groups is expected to achieve signiﬁcant improvements
in accuracy with a lack of bias. This comparison will
provide useful information for designing and conduct-
ing future trials.
Setting and participants
This study is being conducted at Kansai Medical
University Hirakata Hospital and Kansai Medical
University Takii Hospital. Patients with chronic skin
ulcers are being referred by physicians and identiﬁed
through a number of wound care clinics in Osaka
Prefecture and surrounding prefectures.
Inclusion criteria
1. Patients 20 years of age or older with informed
consent.
2. The presence of the following chronic skin ulcers:
– Not healing for at least 1 month with conventional
treatments;
– Not expected to respond to conventional treatments;
– Expected to be closed with autologous skin graft-
ing or suturing after PRP treatment;
– An ulcer area between 3 and 30 cm2 (that can be
applied with autologous PRP).
3. Written informed consent.
Exclusion criteria
1. Patients showing unstable haemodynamics due to
ischaemic heart disease or impaired blood coagula-
tion, as in clotting disorders.
2. Patients taking anticoagulants or antithrombotics
judged by the investigator or subinvestigator to be
inappropriate as participants since the drugs may
affect the clotting system.
3. Any of the following systemic diseases:
– Uncontrolled diabetes mellitus (deﬁned as a gly-
cated haemoglobin level of ≥10% according to the
latest laboratory data obtained within 28 days
before registration);
– Requiring the continued use of oral corticosteroid
therapy (>20 mg/day prednisolone equivalent);
– A history of malignant tumours with a disease-free
interval of 3 years or less.
4. Patients who are or plan to be pregnant.
5. Other patients judged by the investigator or sub-
investigator to be inappropriate as participants of this
study.
Analysis of subgroups
In this study, patients will be randomised to either the
gelatin sheet subgroup or hydrocolloid dressing sub-
group at a ratio of 1:1 without stratiﬁcation.
Randomisation will be performed by assigning random




PRP is prepared using the Magellan Autologous Platelet
Separator System (Medtronic Inc, Minneapolis, Minnesota,
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USA) and its basic disposable kit. PRP is prepared by sam-
pling blood using 60 mL syringes of the basic disposable
kit ﬁlled with an anticoagulant, and separating and con-
centrating platelets to threefold or more compared with
that observed in the peripheral blood using the Magellan
Autologous Platelet Separator System. The obtained PRP
is activated as described in our previous study.8 9 Brieﬂy, a
1:1 (v/v) mixture of 0.5 M CaCl2 (Otsuka Pharmaceutical
Factory, Inc, Tokushima, Japan) and autologous thrombin
is prepared in advance as an activator. A 10:1 (v/v)
mixture of PRP and the activator is incubated for 5 min at
room temperature. Platelets of prepared PRP are counted,
and the concentrations of growth factors (TGF-β1,
PDGF-BB and VEGF) in activated PRP are also quantiﬁed.
If platelets cannot be separated and concentrated three-
fold or more compared with that in the peripheral blood,
the study will be discontinued.
Preparation of the gelatin sheet
Acidic gelatin with an IEP of 5.0 (Nitta Gelatin, Osaka,
Japan) is to be used in this study. Gelatin hydrogel
sheets of 12×3 cm in size are prepared at the
Department of Biomaterial, Field of Tissue Engineering,
Institute for Frontier Medical Sciences, Kyoto
University.16 Brieﬂy, 40 g of aqueous gelatin solution
(5 wt%) preheated at 40°C is mixed with 80 μL of
aqueous glutaraldehyde (GA, Wako Pure Chemical
Industries, Osaka, Japan) solution (25 wt%). The result-
ing mixture is poured into polystyrene dishes and left at
4°C for 12 h for chemical cross-linking of gelatin. Then,
the formed hydrogel sheets are placed in 100 mM
glycine aqueous solution, followed by agitation for 1 h at
room temperature to inactivate the residual unreacted
aldehyde groups of GA. The gelatine hydrogel sheet is
washed with double-distilled water, freeze-dried and steri-
lised with ethylene oxide gas. To remove the remaining
ethylene oxide gas, the resulting hydrogel sheet is kept
at 40°C for 3 days under vacuum conditions.
Application of activated PRP and dressing changes
After debridement of the chronic skin ulcers, activated
PRP is applied to the lesions. Following the administra-
tion of PRP, the wound is dressed with a gelatin hydrogel
sheet or conventional hydrocolloid dressing (DuoActive;
Convatec Japan, Tokyo, Japan). The wound is occluded
with the above dressing material for 5 days from the
beginning of the administration of PRP and treated
thereafter by applying ointment, such as Azunol oint-
ment (Nippon Shinyaku Co Ltd, Kyoto, Japan) or
wound dressings, until 6 weeks after the administration
of PRP.
Subsequent therapy
The use of bFGF will be prohibited starting 3 or more
days prior to the administration of PRP (wash-out period
of bFGF) and during the study period. Negative-pressure
wound therapy must also not be performed during the
study period. After completion of the study period
(6 weeks after PRP administration or the day on which
wound closure is judged to be possible), no particular
restrictions will be imposed. Concomitant therapies,
such as a compression treatment, in cases of venous leg
ulcers, will be continued and applied before entry,
because it is important to evaluate the efﬁcacy of PRP
under the same conditions.
Digital photography for the healing assessment
Using a digital camera, digital images of the wounds will
be taken with a calibrator (CASMATCH; BEAR Medic
Corp, Tokyo, Japan) placed on the skin adjacent to the
wound. The colour and size of the images can be
adjusted using the CASMATCH and an image editing
software program (Adobe Photoshop; Adobe Systems
Inc, California, USA) to assess the wound and granula-
tion areas as well as the wound bed. As with the primary
endpoint, the wound evaluation committee members
will assess the extent of wound closure.
Primary endpoint
The primary endpoint is the ‘time to wound closure’.
Time to wound closure: The time (number of days)
from the administration of PRP to wound closure, spon-
taneous wound closure or wound closure with a simple
surgical procedure. The results of the evaluation will be
conﬁrmed by the wound evaluation committee
members consisting of independent physicians separate
from the physicians involved in the study to ensure
the neutrality, objectivity and reproducibility of the
evaluations.
The evaluation criteria for the possibility of wound
closure during the investigation are as follows:
1. Judged to be closed by spontaneous healing.
2. Judged to be closed using a simple surgical proced-
ure with an ulcer area less than 3 cm2 (when two or
more of the four conditions below are fulﬁlled):
– Seventy-ﬁve per cent or more of the wound area is
covered by granulation tissue.
– Bones, tendons and underlying tissues are covered
with granulation tissue.
– Local infection is controlled clinically (no adverse
events due to infection).
– The wound depth measured by using a depth gauge is
reduced by an average of 50% or more.
Secondary endpoints
▸ Percentage of wound reduction: Before and after the
application of PRP, the wound is photographed once
a week at dressing change, and the wound area is
measured serially.
▸ Degree of improvement in the blood ﬂow: The skin
perfusion pressure or ankle brachial index is mea-
sured at dressing changes before and 1 and 4 weeks
after the application of PRP.
▸ Correlations between the ‘time to wound closure’
and the platelet count or growth factor levels in the
PRP area.
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Blinding
In this study, a data monitoring committee was not orga-
nised, although the wound closure will be independently
measured under blinding by three specialists. The
patients will be unblinded, and unblinded investigators
will apply PRP and the change dressings.
Sample size
This study is a prospective cohort study using historical
data as controls, with a total of 30 patients for registra-
tion, a feasible size for a pilot study.
Study schedule
The schedule of the study assessments and evaluations is
shown in table 1. The study period will be from the day
of PRP application to 6 weeks after PRP application.
Data for evaluating the efﬁcacy and safety of this study
will be collected at enrolment, baseline, day 5 and weeks
1, 2, 3, 4, 5 and 6 after application or the day of wound
closure.
Statistical analysis
The statistical analysis will be performed on the follow-
ing variables:
▸ Time to wound closure;
▸ Percentage of wound reduction;
▸ Improvement in the blood ﬂow;
▸ Correlations of the ‘time to wound closure’ with the
platelet count and/or growth factor levels in the PRP
area;
▸ Adverse events related to the application of PRP.
The efﬁcacy will be evaluated according to the time
from PRP application to wound closure. The survival
curves in an existing control group based on historical
data and the PRP-treated group until wound closure will
be evaluated according to the Kaplan-Meier method,
and a stratiﬁed analysis will be performed using the
log-rank test. A stratiﬁed analysis of the number and per-
centage of patients who show wound closure will be per-
formed using Fisher’s exact test (95% CI).
In addition, the optimal dose of PRP for wound
healing will be estimated from the platelet count and
growth factor concentrations in the PRP area.
The incidences of adverse events, and adverse events
that can be causally related to PRP application, will be
evaluated based on the event and severity. An interim
analyses and auditing will not be planned; however, the
investigators will monitor adverse events and other unin-
tended effects of the trial interventions.
ETHICS
This study is being conducted in compliance with the
ICH-GCP and in agreement with the latest revision of
the Declaration of Helsinki, Pharmaceutical Affairs Law,
and all applicable Japanese laws and regulations, as well
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Participant consent
Informed consent will be obtained from all potential
study participants using the Institutional Review
Board-approved informed consent form. The clinical
investigator informs the potential study participant of all
pertinent aspects of the study, and the participant must
sufﬁciently understand the content of the information
form before providing written consent. The consent
form must be dated and signed by both the investigator
and participant. The participants are also informed that
their medical care will not be affected if they do not
choose to participate in this study. The consent forms
will be retained at Kansai Medical University Hirakata
Hospital and Kansai Medical University Takii Hospital,
and the information form and a copy of the consent
form will be handed to the participant. Whenever the
investigator obtains information that may affect the parti-
cipant’s willingness to continue participation in the
study, the investigator or subinvestigator will immediately
inform the participant and record this observation and
subsequently reconﬁrm the participant’s willingness to
continue participation in the study.
DISSEMINATION
The ﬁndings of this trial will be disseminated through
peer-reviewed journals, and national and international
scientiﬁc meetings as well as to the patients.
DISCUSSION
This study was designed to address the safety and efﬁ-
cacy of PRP treatment for chronic skin ulcers using a
gelatin hydrogel sheet that can sustain the levels of
growth factors in the PRP material. This study will be
the ﬁrst controlled trial to evaluate the efﬁcacy of PRP
covered with a hydrocolloid dressing and PRP covered
with a gelatin sheet in the treatment of chronic skin
ulcers. The efﬁcacy of PRP for the treatment of chronic
wounds in clinical trials is still controversial.10–12 Our
gelatin hydrogel sheet has been applied in clinical trials
mainly as a DDS for bFGF, and its efﬁcacy and safety
have been reported.17 18 bFGF can be used clinically in
Japan; however, the application of bFGF is not approved
in other countries.7 19 20 The clinical usage of growth
factors in these countries is limited. PRP can be pre-
pared from the patient’s blood or donated platelets in
all countries. Some bioengineered skin substitutes that
provide growth factors secreted by living cells have been
reported to be effective for chronic skin ulcers, although
they are costly and access is also limited to only a few
areas.21–23 Our gelatin sheet is freeze-dried and can be
stored at room temperature for months. Therefore, it is
possible to use this combination therapy consisting of
PRP and a gelatin sheet anywhere when needed, and its
efﬁcacy might be superior to that of bioengineered skin
substitutes, as these treatments have a similar mechan-
ism of action in secreting growth factors in a sustained
manner. Regarding the limitation of this study, this study
included ulcers of various causes that could be potential
for bias by different concomitant therapies. Therefore,
we will plan the clinical study limited to one ulcer cause
with standardised concomitant therapy in the next step.
This is our ﬁrst trial using the PRP/gelatin hydrogel
sheet and we focused mainly on safety in this study, and
evaluate the efﬁcacy in the next step limited to one
ulcer cause.
If successful, this intervention may lead to substantial
and important changes in the management of increas-
ingly prevalent chronic skin ulcers, such as diabetes
ulcers and venous leg ulcers.
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